Highest-materiality recent filing
Penumbra Q2 revenue $390M (+14.9% YoY); net income $34.8M; pending BSX acquisition
Revenue $390.0M, up 14.9% YoY; global thrombectomy $259.0M (+12.5%), embolization & access $131.1M (+20.0%).
Penumbra shareholders approve merger with Boston Scientific; vote 28.6M for, 85k against
Special meeting held May 6, 2026; 28,665,933 shares present, quorum achieved.
Revenue $374.8M, up 15.6% YoY; thrombectomy $253.9M (+12.1%), embolization & access $120.8M (+23.8%).
Penumbra Q4 revenue $385.4M (+22.1%); operating income $59.2M; FY25 rev $1.4B (+17.5%)
Revenue $385.4M for Q4, up 22.1% YoY (20.9% constant currency). US Thrombectomy $203.1M (+12.4%).
Boston Scientific to acquire Penumbra: $374 cash or 3.8721 BSX shares per share; 73% cash/27% stock
Penumbra holders elect $374 cash or 3.8721 BSX shares per share; proration targets 73.26% cash/26.74% stock.
Penumbra Q3 revenue $354.7M (+17.8% YoY); full-year guidance raised to $1.375-1.380B
Net income of $45.9M; adjusted EBITDA $66.7M (18.8% margin).
Penumbra promotes Shruthi Narayan to President, CEO remains Elsesser
Shruthi Narayan, former President Interventional, becomes President effective Sept 1, 2025; reports to CEO Adam Elsesser.
Penumbra Q2 revenue $339.5M (+13.4% YoY); net income $45.3M vs prior-year loss
Revenue $339.5M, +13.4% YoY; U.S. Thrombectomy $188.5M (+22.6%); U.S. VTE +42%.
Penumbra Q1 2025 revenue $324.1M (+16.3% YoY); net income $39.2M; raises U.S. thrombectomy guidance
Revenue $324.1M (+16.3% YoY); U.S. Thrombectomy $187.9M (+25.0%).
Penumbra Q4 adjusted revenue $321.3M (+13%); U.S. thrombectomy up 27%
Adjusted revenue (excl. Italian payback) Q4 $321.3M, up 12.9% YoY; reported revenue $315.5M (+10.8%).
Penumbra Q3 revenue $301M (+11.1% YoY); U.S. thrombectomy up 21.2%; raises segment guidance
Revenue $301.0M, +11.1% YoY; net income $29.5M; adjusted EBITDA $56.7M (18.8% margin).
Penumbra announces $200M share repurchase authorization, $100M accelerated buyback
Board authorized up to $200M in stock repurchases through July 31, 2025.
Penumbra Q2 revenue $299.4M (+14.5%); loss from ops $81M on $110.3M impairment charges
U.S. thrombectomy revenue $153.7M, up 24.9% YoY; global thrombectomy revenue $203.5M (+25.2%).
Penumbra Q1 revenue $278.7M (+15.4% YoY); U.S. thrombectomy up 35.2%; reaffirms FY24 guidance
Revenue $278.7M, up 15.4% YoY (15.2% constant currency); U.S. thrombectomy $150.3M, +35.2%.
Penumbra Q4 revenue $284.7M (+28.7%); thrombectomy sales up 42.4%
Revenue of $284.7M in Q4 2023, up 28.7% YoY; full-year $1,058.5M, up 25.0%.
Penumbra Q3 revenue $270.9M (+26.8% YoY); raises full-year revenue guidance to $1.05B-$1.07B
Revenue $270.9M (+26.8% YoY, +25.9% constant currency); thrombectomy products revenue $179.1M (+38.0% YoY).
Penumbra Q2 revenue $261.5M +25.5% YoY; raises FY2023 guidance to $1.05-1.07B
Revenue $261.5M (+25.5% YoY constant currency), U.S. 71%, international 29%.
Penumbra Q1 revenue $241.4M (+18.4%); raises FY 2023 guidance to $1.04-1.06B
Revenue $241.4M (+18.4% YoY, +19.7% constant currency); vascular $142.8M, neuro $98.5M.
Penumbra Q4 2022 revenue $221.2M, up 8.4% YoY; operating income $4.8M vs loss $40.1M
Q4 revenue $221.2M (+8.4% YoY, +10.5% constant currency); full year $847.1M (+13.3%).
Penumbra Q3 rev $213.7M (+12.4%); cuts FY22 guide to $840-845M on Flash delay, FX headwind
Revenue $213.7M, +12.4% YoY (+15.1% constant currency); vascular +17%, neuro +6.7%.
Penumbra Q2 revenue $208.3M (+13.1% YoY); GAAP operating loss vs prior-year income
Revenue $208.3M, up 13.1% (15.3% constant currency); vascular $123.5M (+22.7%), neuro $84.8M (+1.5%).
Penumbra Q1 2022: Revenue up 20.5% to $203.9M; operating loss of $4.0M vs income of $13.5M
Revenue $203.9M, up 20.5% YoY (21.8% constant currency).
Penumbra Q4 2021 revenue $204M (+22% YoY); GAAP op loss $40.1M, adjusted op income $2.5M
Q4 revenue $204.0M (+22.2% YoY; +23.0% constant currency); US $144.5M (+23.7%).
Penumbra Q3 revenue $190.1M (+26%), swings to operating profit; raises FY guidance
Revenue $190.1M, +25.8% YoY (+25.6% constant currency); US 71%, international 29%.
Penumbra completes acquisition of Sixense Enterprises for ~$300M in stock and options
Merger closed Oct 1, 2021; Sixense becomes wholly owned subsidiary of Penumbra.
Penumbra enters M&A with Sixense; issues ~600K shares + options worth ~$300M
Issues ~600,000 shares of common stock valued at ~$170 million based on $280.88 VWAP.
Penumbra Q2 revenue $184.3M (+75.3% YoY); raises FY2021 guidance to $720-730M
Revenue $184.3M (+75.3% YoY); vascular $100.7M (+117.6%), neuro $83.6M (+42.0%).
On February 14, 2025, Don Kassing, a member of the Board of Directors (the “Board”) of Penumbra, Inc. (the “Company”), notified the Company that he will retire from the Board effective April 1, 2025.
Lynn Rothman, the Executive Vice President and Chief Business Officer of Penumbra, Inc. (the “Company”), notified the Company of her departure, effective May 2, 2022
Max materiality 1.00 · Median 0.75 · Most common event earnings